Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Garcia-Sanz on Combination Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

August 15th 2018

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses combination chemotherapy in patients with Hodgkin lymphoma.

FDA Grants SL-401 Priority Review for Rare Hematologic Cancer

August 13th 2018

The FDA has granted a priority review designation to a biologics license application for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

August 10th 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.

Dr. Barrientos on Advances in the Treatment Landscape for Patients With CLL

August 8th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in Myeloma

August 8th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

August 8th 2018

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

FDA Approves Mogamulizumab for CTCL

August 8th 2018

The FDA has approved mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. Flinn on the iNNOVATE Trial in Waldenstrom Macroglobulinemia

August 8th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

Dr. O'Brien on Sequencing Small Molecule Inhibitors in CLL

August 6th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Kurtz Discusses Using ctDNA to Detect Lymphoma

August 3rd 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA to detect lymphoma.

Frontline Guadecitabine Falls Short in Phase III AML Study

August 3rd 2018

Guadecitabine (SGI-110) did not meet the coprimary endpoints of the phase III ASTRAL-1 study comparing the hypomethylating agent with physician’s choice of standard therapy in treatment-naïve adult patients with AML.

Dr. Kambhampati on Updates in Myeloma from the 2018 ASCO Annual Meeting

August 2nd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

Dr. Jabbour Discusses Blinatumomab in ALL

August 2nd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

FDA Grants Quizartinib Breakthrough Designation for FLT3-ITD+ AML

August 1st 2018

The FDA has granted a breakthrough therapy designation to quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Dr. Smith Discusses Double-Hit and Triple-Hit Lymphoma

July 31st 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

EU Panel Backs Frontline Daratumumab/VMP Combo for Multiple Myeloma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Pollyea Discusses Recent Advances in AML

July 27th 2018

Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.

Dr. Ansell Discusses Immune Evasion in Lymphoma

July 27th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).